Dry powder inhalers: An overview

Respiratory Care

Volumn 50, Issue 10, 2005, Pages 1304-1312

  Atkins, Paul J ^a  

^a Oriel Therapeutics Inc   (United States)

Author keywords

Aerosol; Asthma; Bronchodilator; Chronic obstructive pulmonary disease; COPD; Corticosteroids; DPI; Drug delivery; Dry powder inhaler; Lactose

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; INSULIN; MOMETASONE FUROATE; SALBUTAMOL; SALMETEROL; SALMETEROL XINAFOATE; TERBUTALINE; TIOTROPIUM BROMIDE; ZANAMIVIR; BRONCHODILATING AGENT;

AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRY POWDER; EUROPE; HUMAN; IN VIVO STUDY; INFLUENZA; METERED DOSE INHALER; PARTICLE SIZE; PATIENT COMPLIANCE; POWDER INHALER; QUALITY CONTROL; SINGLE DRUG DOSE; UNITED STATES; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; REVIEW;

ADMINISTRATION, INHALATION; AEROSOLS; ASTHMA; BRONCHODILATOR AGENTS; CHEMISTRY, PHARMACEUTICAL; HUMANS; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33644644745     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. GlaxoSmithKline. Advair Diskus 100/50 (fluticasone 100mcg and salmeterol 50mcg inhalation powder). http://www.advair.com. Accessed August 4, 2005.
2. Molina M, Rowland F. Stratospheric sink for chlorofluro-methanes: chlorine atom catalysed destruction of ozone. Nature 1974;249:810-812.
3. Tezky T, Holquist C. Misadministration of capsules for inhalation. Drug Topics 2005;4:48.
4. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004;1(1):67-86.
5. Sumby B, Slater A, Atkins PJ, Prime D. Review of dry powder inhalers. Adv Drug Deliv Rev 1997;26(1):51-58.
6. Meakin BJ, Ganderton D, Panza I, Ventura P. The effect of flow rate on drug delivery from the Pulvinal, a high resistance dry powder inhaler. J Aerosol Med 1998;11(3):143-152.
7. De Boer AH, Winter HMI, Lerk CF. Inhalation characteristics and their effect on in-vitro drug delivery from dry powder inhalers. Int J Pharm 1996;130:231-244.
8. Bell JH, Hartley PS, Cox JS. Dry powder aerosols. I. A new powder inhalation device J Pharm Sci 1971;60(10):1559-1564.
9. Newman SP. Therapeutic aerosols. In: Clarke SW, Pavia D, editors. Aerosols and the lung: clinical and experimental aspects. London: Butterworths; 1984:87.
10. Clark T, Rees J. Practical management of asthma. London: Martin Dunitz; 1985:134.
11. Schering-Plough. Foradil Aerolizer (formoterol fumerate inhalation powder) 12mcg. http://www.foradil.com. Accessed April 2005.
12. Boehringer Ingelheim/Pfizer. Spiriva Handihaler (tiotropium bromide inhalation powder). http://www.spiriva.com. Accessed April 2005.
13. Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 1988;5(8):506-508.
14. Newman SP, Moren F, Crompton GK, editors. A new concept in inhalation therapy. London: Medicom; 1987.
15. AstraZeneca. Pulmicort Turbuhaler (budesonide inhalation powder) 200mcg. http://www.twistclickinhale.com. Accessed April 2005.
16. Everard ML, Devadason SG, Le Souef PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med 1997;91(10):624-628.
17. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther 2003;16(2):79-95.
18. Schering-Plough, 31st March 2005, approval of Asmanex Twisthaler 220 meg (mometasone furoate inhalation powder). http://www.schering-plough.com. Accessed August 4, 2005.
19. Pover GM, Langdon CG, Jones SR, Fidler C. Evaluation of a breath operated powder inhaler. J Int Med Res 1988;16(3):201-203.
20. Crompton GK. Delivery systems. In: Kay AB, editor. Allergy and allergic diseases. London: Blackwell Science; 1997:1440-1450.
21. Brindley A, Sumby BS, Smith IJ, Prime D, Haywood PA, Grant AC. Design manufacture and dose consistency of the Serevent Diskus inhaler. Pharm Tech Eur 1995;7:14-22.
22. Schlaeppi M, Edwards K, Fuller RW, Sharma R. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Prac 1996;50(1):14-19.
23. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003;16(3):249-254.
24. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care 2005;50(9):1209-1227.
25. Melani AS, Zanchetta D, Barbato N, Sestini P, Cinti C, Canessa PA, et al; Associazione Italiana Pneumologi Ospedalieri Educational Group. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol 2004;93(5): 439-446.
26. Moore AC, Stone S. Meeting the needs of patients with COPD: patients' preference for the Diskus inhaler compared with the Handihaler. Int J Clin Pract 2004;58(5):444-450.
27. Concessio NM, Hickey AJ. Descriptors of irregular particle morphology and powder properties. Adv Drug Deliv Rev 1997;26(1):29-40.
28. Brown K. The formulation and evaluation of powders for inhalation. In: Ganderton D, Jones TM, editors. Drug delivery to the respiratory tract 1987. Chichester, England: Ellis Horwood. 1987:119-123.
29. Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB. Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 2002;19(3):239-245.
30. Crowder TM, Louey MD, Sethuraman VV, Smyth HD, Hickey AJ. An odyssey in inhaler formulations and design. Pharm Technol 2001; 25(7):99-113.
31. Peart J, Clarke MJ. New developments in dry powder inhaler technology. Am Pharm Rev 2001;4(3):37-45.
32. Koushik K, Kompella UB. Inhalation engineering. Drug Deliv Technol 2004;4(2):40-50.
33. Sanders M. Inhalatorium. http://inhalatorium.com. Accessed April 30, 2005.
34. Anderson PJ. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir Care 2005;50(9):1139-1149.
35. Nowak-Wegrzyn A, Shapiro GG, Beyer K, Bardina L, Sampson HA. Contamination of dry powder inhalers for asthma with milk proteins containing lactose (letter). J Allergy Clin Immunol 2004;113(3): 558-560.
36. Chuchalin AG, Manjra AI, Rozinova NN, Skopkova O, Cioppa GD, Till D, et al. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma. J Aerosol Med 2005;18(1):63-73.
37. Crowder TM. Vibration technology for active dry-powder inhalers. Pharm Technol 2004:2-6.